Talha Badar

Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase

Talha Badar, Hagop M. Kantarjian, Farhad Ravandi et al. · Leukemia Research · 2015 · 79 citations · Full text

Hematological Malignancy, Therapeutic Benefit, High-risk Primary Myelofibrosis +9

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

Reid W. Merryman, Luca Castagna, Laura Giordano et al. · Leukemia · 2021 · 77 citations

Lymphoid Neoplasia, Transplantation, Medicine +7

Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients

Naseema Gangat, Omer Karrar, Moazah Iftikhar et al. · American Journal of Hematology · 2023 · 67 citations · Full text

Survival of TP53-mutated acute myeloid leukemia patients receiving allogeneic stem cell transplantation after first induction or salvage therapy: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Talha Badar, Ehab Atallah, Rory M. Shallis et al. · Leukemia · 2023 · 53 citations

Hematological Malignancy, Neoplastic Diseases, Transplantation +10

Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes

Talha Badar, Keyur P. Patel, Philip A. Thompson et al. · Leukemia Research · 2015 · 52 citations · Full text

Mutation-based Testing, Engineering, Somatic Variant +9